Last reviewed by Dr. Dharmender Malik on 14 May 2026 · this article reflects the published primary literature and current clinical practice at FMRI Gurugram.
Introduction
Peptide-receptor radionuclide therapy — PRRT — is the established radioligand treatment for somatostatin receptor-positive neuroendocrine tumours. Lu-177 DOTATATE (branded as Lutathera) was the first radiopharmaceutical to receive both FDA and EMA approval for gastroenteropancreatic NETs based on the randomised NETTER-1 trial, and the indication was expanded in 2024 to earlier disease settings following NETTER-2. This article walks through what PRRT actually is, who it's offered to, what the randomised trials show with specific endpoint figures, what the four-cycle treatment course involves, and where PRRT sits in the wider NET treatment sequence — each statement traced to a peer-reviewed publication or regulatory filing.
What PRRT is — the basic mechanism
AI Overview · short answer
Peptide-receptor radionuclide therapy (PRRT) with Lu-177 DOTATATE is a systemic radioligand therapy approved by the FDA (2018) and EMA (2017) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours[1][2]. Eligibility is determined by Ga-68 DOTATATE PET-CT, which confirms somatostatin receptor expression. The standard course is four cycles of 7.4 GBq (200 mCi) Lu-177 DOTATATE at 8-week intervals, given with concurrent amino acid infusion for renal protection. The pivotal NETTER-1 trial in midgut NETs reported a progression-free survival hazard ratio of 0.21 (a meaningful reduction in progression risk) and significant quality-of-life benefit[3]. The 2024 NETTER-2 trial extended eligibility to grade 2/3 gastroenteropancreatic NETs in the first-line setting[4].
PRRT consists of three structural elements coupled together as a single molecule[5]:
- A targeting peptide — DOTATATE (or DOTATOC, DOTANOC) — that binds somatostatin receptor subtype 2 (SSTR2) on neuroendocrine tumour cells. NETs typically overexpress SSTR2 at densities far higher than most normal tissues, which is what makes them targetable.
- A chelator — DOTA — that holds the radionuclide securely while the molecule circulates in the bloodstream.
- The radionuclide — Lutetium-177 — a beta-emitter with a half-life of approximately 6.65 days and a mean beta range in tissue of approximately 0.7 mm.
After intravenous infusion, the radioligand circulates briefly, binds SSTR2 on NET cells, is internalised into the cell, and delivers short-range beta radiation locally to the tumour. Because the targeting is selective and the beta range is short, surrounding non-receptor-expressing tissue receives substantially less dose than the tumour. Lu-177 also emits low-yield gamma photons (113 keV at 6%, 208 keV at 10%), which allow post-therapy SPECT/CT imaging to confirm that the radioligand reached the intended tumour sites[5].
Who PRRT is offered to
PRRT eligibility is established by current label and guideline criteria[2][6]:
- Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours — including midgut, pancreatic, foregut, and hindgut NETs, with somatostatin receptor expression confirmed on Ga-68 DOTATATE (or DOTATOC) PET-CT.
- Inoperable or metastatic disease — PRRT is not first-line for resectable localised NET; surgical management remains the standard where curative resection is feasible.
- Disease progression on first-line somatostatin analogue therapy (e.g., octreotide LAR, lanreotide) for indolent / well-differentiated NETs — the original NETTER-1 setting. NETTER-2 has extended use to first-line in higher-grade (grade 2/3) GEP-NETs.
- Adequate organ function — preserved renal function (typically eGFR > 50 mL/min), adequate marrow reserve, acceptable liver function.
- Acceptable performance status — typically ECOG 0–2.
Other clinical settings where PRRT is used under specific protocols include bronchopulmonary NETs, paragangliomas / pheochromocytomas (with appropriate alpha-blockade), and selected SSTR-positive disease in other primary sites — these uses are increasingly evidence-supported but vary by guideline and centre[7].
Eligibility imaging — Ga-68 DOTATATE PET-CT
Every PRRT eligibility decision is anchored to Ga-68 DOTATATE PET-CT imaging[8]. The scan does three things simultaneously:
- Confirms somatostatin receptor expression — quantified semi-quantitatively as SUVmax across disease sites. A widely-used clinical threshold is tumour SUVmax greater than liver SUVmax (modified Krenning score 3-4), though precise eligibility decisions are made by multidisciplinary review rather than a single number.
- Maps disease distribution — confirms candidates have somatostatin-receptor-positive disease across the body, not just one site.
- Identifies discordant disease — lesions visible on conventional imaging that show no Ga-68 DOTATATE uptake may represent more poorly differentiated or higher-grade phenotypes that are less likely to respond to PRRT. In selected cases, an additional FDG PET-CT is performed to characterise such lesions.
The Ga-68 DOTATATE PET-CT also serves as the baseline against which post-treatment response will be assessed. For more on what to expect from this scan specifically, see our companion Ga-68 DOTATATE PET-CT article.
NETTER-1 (Strosberg et al., NEJM 2017) — the pivotal trial
NETTER-1 was the phase III randomised trial that established the regulatory and clinical evidence base for Lu-177 DOTATATE in midgut NETs. The trial randomised 229 patients with well-differentiated, advanced, somatostatin receptor-positive midgut neuroendocrine tumours that had progressed on first-line octreotide LAR. Randomisation was 1:1 to four cycles of Lu-177 DOTATATE 7.4 GBq plus octreotide LAR 30 mg vs high-dose octreotide LAR 60 mg[3]:
| Endpoint | Lu-177 DOTATATE + octreotide | High-dose octreotide | Statistical comparison |
|---|
| Progression-free survival | Not reached at primary analysis | 8.4 months | HR 0.21, 95% CI 0.13-0.33, p<0.001 |
| Objective response rate | 18% | 3% | p<0.001 |
| Estimated 20-month PFS rate | 65.2% | 10.8% | — |
| Quality of life (global health status) | Improved | — | Significant favouring PRRT |
The NETTER-1 final overall survival update (Strosberg et al., Lancet Oncology 2021) reported median overall survival of 48.0 months in the Lu-177 DOTATATE arm versus 36.3 months in the control arm — a difference that did not meet the prespecified statistical significance threshold (HR 0.84, 95% CI 0.60-1.17) but was directionally favourable, with a notable rate of cross-over to PRRT in the control arm complicating interpretation[9].
NETTER-2 (Singh et al., Lancet 2024) — earlier-setting evidence
NETTER-2 was the phase III randomised trial that extended Lu-177 DOTATATE eligibility into the first-line setting for higher-grade GEP-NETs. The trial randomised 226 patients with grade 2 or grade 3 well-differentiated GEP-NETs (Ki-67 10-55%) to either Lu-177 DOTATATE 7.4 GBq × 4 cycles plus octreotide LAR 30 mg, or high-dose octreotide LAR 60 mg alone, as first-line therapy[4]:
| Endpoint | Lu-177 DOTATATE + octreotide | High-dose octreotide | Statistical comparison |
|---|
| Median progression-free survival | 22.8 months | 8.5 months | HR 0.276, 95% CI 0.182-0.418, p<0.0001 |
| Objective response rate | 43.0% | 9.3% | p<0.0001 |
| Treatment-related grade 3-4 adverse events | Manageable; pattern consistent with NETTER-1 | Lower frequency | — |
NETTER-2 led to a 2024 FDA label expansion for Lu-177 DOTATATE to include first-line use in adults with grade 2/3 advanced GEP-NETs[10]. The clinical implication is that, for patients with appropriately characterised higher-grade disease, PRRT can be considered earlier in the treatment sequence rather than reserved for second-line use after somatostatin analogue progression.
The four-cycle treatment protocol
The standard PRRT course is four cycles of 7.4 GBq (200 mCi) Lu-177 DOTATATE at 8-week intervals, totalling approximately 32 weeks of active therapy[2]. Each cycle follows a consistent structure:
- Pre-cycle workup — kidney function (eGFR), marrow counts, liver function, chromogranin A, biochemical markers if functional tumour.
- Renal protection — concurrent intravenous amino acid infusion (lysine and arginine) starts approximately 30 minutes before the Lu-177 DOTATATE infusion and continues during and after. This is critical: amino acids compete with the radioligand for proximal tubule reabsorption, reducing renal radiation dose. Skipping or shortening amino acid infusion is not appropriate.
- Lu-177 DOTATATE infusion — the radioligand is infused slowly over approximately 30 minutes through a separate IV line from the amino acids.
- Anti-emetic and supportive care — typically ondansetron prophylaxis; some centres add additional anti-emetic agents because amino acid infusion can cause nausea.
- Post-administration imaging — Lu-177 SPECT/CT (typically next day or within 24-48 hours) confirms intended tumour distribution.
- Inter-cycle monitoring — biochemistry and blood counts at intervals between cycles to detect any developing renal or marrow toxicity.
Most patients are admitted for a short stay (24-72 hours) per cycle for monitoring, radiation safety counselling, and discharge instructions. Centres in regulated jurisdictions follow EANM procedure guidelines for Lu-177 DOTATATE administration[11].
Side-effect profile and monitoring
PRRT side effects were characterised across NETTER-1, NETTER-2, and multiple long-term cohort studies including the Bodei series of 807 patients[12]:
| Side effect | Frequency & severity | Monitoring & management |
|---|
| Acute nausea (during amino acid infusion) | Common; usually mild-moderate | Anti-emetic prophylaxis |
| Fatigue | Common; usually mild-moderate; resolves over days-weeks | Supportive management |
| Cytopenia (anaemia, thrombocytopenia, lymphopenia) | Common (any grade); usually mild; grade 3-4 less common | Pre-cycle and inter-cycle blood counts |
| Renal effects | Uncommon with amino acid renoprotection; risk higher in patients with pre-existing CKD | Pre-treatment eGFR; long-term renal function monitoring |
| Carcinoid crisis (in functional midgut NETs) | Uncommon but recognised | Octreotide pre-medication for high-risk patients |
| Hormonal symptoms (functional tumour flare) | Uncommon early in treatment | Continued somatostatin analogue cover; supportive management |
| Therapy-related myeloid neoplasm (t-MDS / t-AML) | Rare; cumulative risk approximately 2% in long-term Bodei cohort follow-up | Long-term marrow monitoring; discussed in informed consent |
| Hair thinning | Uncommon; mild and usually temporary | Supportive only |
Most patients tolerate the four-cycle course well; treatment delays for cytopenia or other reasons are common but rarely require discontinuation. For detailed cross-therapy comparison of side-effect profiles see our companion side effects of nuclear medicine treatment article.
Response assessment and follow-up
PRRT response is assessed using a combination of biochemical, imaging, and clinical endpoints[13]:
- Biochemical response — chromogranin A, 5-HIAA (for midgut serotonin-producing tumours), insulin / gastrin / glucagon / VIP for functional pancreatic NETs.
- Imaging response — restaging CT or MRI at intervals (commonly 3 months post-cycle 4, then 6-monthly). Ga-68 DOTATATE PET-CT may be repeated to reassess receptor-positive disease and inform potential retreatment.
- Symptom response — patient-reported relief of carcinoid syndrome, abdominal pain, weight loss, performance status — particularly important for functional tumours where symptom burden often dominates the disease experience.
- RECIST and modified RECIST — formal trial response criteria for objective response classification (CR / PR / SD / PD).
Response patterns after PRRT often differ from chemotherapy responses: tumours frequently show prolonged stable disease rather than dramatic shrinkage, and the most clinically meaningful endpoint is often time-to-progression rather than peak tumour shrinkage. This is one reason that PFS rather than objective response rate was the primary endpoint of NETTER-1 and NETTER-2[3][4].
Where PRRT sits in the NET treatment sequence
NET management is sequential and depends on disease grade, distribution, functionality, and prior treatments. PRRT's position has expanded with NETTER-2[14]:
- Curative-intent surgery — first-line for resectable localised NETs.
- Somatostatin analogues (octreotide LAR, lanreotide) — first-line systemic therapy for unresectable / metastatic well-differentiated grade 1 NETs; established by the PROMID and CLARINET trials.
- PRRT (NETTER-2 setting) — first-line systemic therapy for higher-grade (grade 2/3) advanced GEP-NETs since 2024.
- PRRT (NETTER-1 setting) — second-line for midgut NETs progressing on somatostatin analogues.
- Locoregional therapy — Y-90 TARE for liver-dominant disease (see our Y-90 article), TACE, ablation, or surgical debulking.
- Targeted therapy — everolimus (mTOR inhibitor; RADIANT trials), sunitinib (pancreatic NETs).
- Chemotherapy — typically platinum-etoposide for high-grade or poorly differentiated neuroendocrine carcinoma; capecitabine-temozolomide for selected pancreatic NETs.
- Retreatment / salvage PRRT — under emerging evidence, retreatment with additional cycles after initial PRRT course is possible in selected patients with documented response and adequate residual marrow/renal reserve.
The optimal sequence for any individual patient is determined by multidisciplinary tumour-board review including medical oncology, surgical oncology, nuclear medicine, and gastroenterology / hepatology.
Indian published cohort experience
Indian institutional series have contributed substantially to the published PRRT evidence base, both for routine indications and for extended applications[15]:
- AIIMS New Delhi — Yadav and colleagues have published one of the largest single-institution Lu-177 DOTATATE cohorts in Asia, with response rates and tolerability profiles broadly consistent with NETTER-1 international data[15].
- Tata Memorial / BARC — Basu and colleagues have published on Indian indigenous production of Lu-177 and on PRRT outcomes including in less-commonly-treated NET subtypes[16].
- Multi-centre Indian audits — the Indian College of Nuclear Medicine has documented growing PRRT delivery capacity across tertiary centres including FMRI Gurugram, with consistent adherence to EANM procedure guidelines and AERB safety codes[17].
Indian centres typically deliver Lu-177 DOTATATE using either BRIT-sourced Lu-177 with in-house DOTATATE compounding, or imported Lu-177 with compounded preparation, depending on supply availability — both pathways under DCGI permissions and AERB licensure.
The bottom line
- Lu-177 DOTATATE PRRT (Lutathera) is approved for somatostatin receptor-positive gastroenteropancreatic NETs based on the NETTER-1 trial; the 2024 NETTER-2 trial extended approval to first-line use in grade 2/3 GEP-NETs[3][4].
- NETTER-1 reported PFS HR 0.21 (95% CI 0.13-0.33) and objective response rate 18% vs 3% with high-dose octreotide[3].
- NETTER-2 reported median PFS 22.8 months vs 8.5 months (HR 0.276) and objective response rate 43.0% vs 9.3%, leading to the 2024 first-line label expansion[4].
- Standard course is four cycles of 7.4 GBq Lu-177 DOTATATE at 8-week intervals with concurrent amino acid infusion for renal protection[2].
- Eligibility is anchored to Ga-68 DOTATATE PET-CT confirming somatostatin receptor expression; FDG PET may be added in higher-grade or discordant cases[8].
- Side-effect profile is generally favourable: fatigue, mild cytopenia, amino acid-infusion nausea are common; rare long-term risks include therapy-related myeloid neoplasm (~2% cumulative in long-term follow-up)[12].
- Indian published cohorts (AIIMS, Tata Memorial / BARC) have reported PRRT response and tolerability broadly consistent with international NETTER-1 data[15].
Important
This article is general information about Lu-177 DOTATATE PRRT for neuroendocrine tumours. Individual eligibility requires formal multidisciplinary review including nuclear medicine, medical oncology, gastroenterology, and surgical oncology. Treatment plans depend on tumour grade, distribution, functional status, organ reserve, and prior therapy.
"PRRT is not a single treatment — it is a four-cycle, eight-month structured therapy that begins with a Ga-68 DOTATATE PET-CT, runs through dosimetry, renal protection, and post-cycle imaging, and ends with structured follow-up. NETTER-1 and NETTER-2 give us the trial evidence; the multidisciplinary team gives the individual patient their sequence."
Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI
PRRT eligibility & dosimetry review · FMRI
At FMRI Gurugram, PRRT candidacy review covers Ga-68 DOTATATE PET-CT (receptor expression, disease distribution), baseline kidney function, marrow reserve, prior treatment history, functional-tumour status, and multidisciplinary review with medical oncology, gastroenterology, and surgical oncology. Eligibility decisions follow EANM procedure guidelines.
Request PRRT eligibility review · WhatsApp +91 8800 988936
For patients & referring clinicians
Frequently asked questions
Q01
What is PRRT?
PRRT stands for peptide-receptor radionuclide therapy. It is a systemic radioligand therapy in which a targeting peptide (DOTATATE) bound to a radioactive isotope (Lutetium-177) is infused intravenously. The peptide binds somatostatin receptor 2 on neuroendocrine tumour cells, is internalised, and the Lu-177 delivers short-range beta radiation locally to the tumour while sparing most surrounding tissue. The most commonly used form is Lu-177 DOTATATE, branded as Lutathera [1][5].
Q02
Is PRRT a type of radiation therapy?
Yes — PRRT is a form of systemic radiation therapy, often called molecular radiotherapy or radioligand therapy. Unlike conventional external-beam radiation that comes from a machine outside the body and targets a specific anatomical area, PRRT delivers radiation through an intravenous radioactive molecule that travels through the bloodstream and binds to disease-specific receptors. The radiation is then delivered locally at each receptor-positive site throughout the body [5].
Q03
What is the survival rate after PRRT?
The NETTER-1 final overall survival analysis (Strosberg et al., Lancet Oncology 2021) reported median overall survival of 48.0 months in the Lu-177 DOTATATE arm vs 36.3 months in the high-dose octreotide arm, with a hazard ratio of 0.84 (95% CI 0.60-1.17). The difference did not meet statistical significance, partly because a notable proportion of control-arm patients crossed over to PRRT. PFS was the trial's primary endpoint and was strongly positive (HR 0.21) [3][9]. Individual prognosis varies substantially with tumour grade, burden, prior treatments, and Ki-67 index.
Q04
What are the side effects of PRRT therapy?
Most common: fatigue, mild-moderate nausea during the amino acid infusion (anti-emetic prophylaxis is routine), and mild cytopenia (anaemia, thrombocytopenia, lymphopenia). Less common: renal effects (uncommon with proper amino acid renoprotection), carcinoid crisis (in functional midgut NETs, mitigated by octreotide pre-medication), and functional tumour flare. Rare but recognised long-term: therapy-related myeloid neoplasm (cumulative risk approximately 2% in the long-term Bodei et al. cohort of 807 patients) [12].
Q05
How many cycles of PRRT will I need?
The standard licensed protocol is four cycles of 7.4 GBq (200 mCi) Lu-177 DOTATATE at 8-week intervals — approximately 32 weeks of active therapy. This is the protocol evaluated in both NETTER-1 and NETTER-2. Some patients receive fewer cycles if unacceptable toxicity occurs; selected patients with continued response and adequate organ reserve may be considered for retreatment cycles under emerging protocols [2][3][4].
Q06
Why is amino acid infusion given during PRRT?
Amino acids (lysine and arginine) compete with Lu-177 DOTATATE for reabsorption in the proximal tubule of the kidneys, reducing renal radiation dose. Concurrent IV amino acid infusion starting approximately 30 minutes before the Lu-177 DOTATATE infusion and continuing during and after is mandatory under EANM procedure guidelines — it is the principal renal-protection measure during PRRT [11].
Q07
What does NETTER-2 add to NETTER-1?
NETTER-1 (NEJM 2017) established Lu-177 DOTATATE in second-line midgut NETs progressing on octreotide. NETTER-2 (Lancet 2024) extended use to first-line in higher-grade (grade 2 and grade 3, Ki-67 10-55%) GEP-NETs, reporting median PFS 22.8 months vs 8.5 months and objective response 43.0% vs 9.3% versus high-dose octreotide. The FDA expanded the Lutathera label in 2024 to include this first-line indication [4][10].
Q08
How long am I radioactive after PRRT?
Lu-177 has a physical half-life of approximately 6.65 days; biological clearance further reduces the body's radioactivity. External radiation exposure to family members is low and manageable with brief common-sense distancing for the first few days. Specific written discharge instructions covering distance, sleeping arrangements, bathroom use, and contact with pregnant women and young children are provided after each cycle — these are typically less restrictive than those for high-dose I-131 thyroid therapy.
Q09
Is PRRT covered by insurance?
Coverage varies by country, policy, and indication. In countries where Lu-177 DOTATATE (Lutathera) has regulatory approval (FDA 2018, EMA 2017), it is generally covered for the approved indications, subject to policy terms and pre-authorisation. The 2024 FDA label expansion to first-line in grade 2/3 GEP-NETs broadens insurance-covered eligibility in the US. In India, coverage varies by policy and treating centre arrangement; patients should confirm coverage with their insurer before therapy [1][10].
Q10
What does response to PRRT typically look like on follow-up imaging?
Response patterns after PRRT often differ from chemotherapy responses. Tumours frequently show prolonged stable disease with modest size reduction rather than dramatic shrinkage. NETTER-1 reported objective response rate 18% and NETTER-2 reported 43%. Many patients show stable disease for extended periods — which is why progression-free survival, rather than objective response, was the primary endpoint of both trials. Restaging typically uses CT or MRI at intervals plus Ga-68 DOTATATE PET-CT for receptor-positive disease assessment [3][4][13].
Q11
Can PRRT be repeated if I respond and then progress?
Retreatment with additional cycles of Lu-177 DOTATATE after initial four-cycle PRRT course is feasible in selected patients with documented prior response, adequate residual marrow and renal reserve, and continued somatostatin receptor expression on Ga-68 DOTATATE PET-CT. The evidence base for retreatment is more limited than for first-course PRRT and decisions are made on a case-by-case basis at multidisciplinary review [13].
Q12
How do I begin a PRRT eligibility review at FMRI?
At FMRI Gurugram, PRRT candidacy review covers Ga-68 DOTATATE PET-CT (receptor expression, disease distribution), baseline kidney function and marrow reserve, prior treatment history, functional-tumour status, and multidisciplinary review with medical oncology, gastroenterology, and surgical oncology. Eligibility decisions follow EANM procedure guidelines. WhatsApp +91 8800 988936 to begin a confidential review.
Citations & references
All clinical numbers above are sourced from the primary literature listed below. Every reference links to the open journal page or the regulatory archive — open in a new tab to verify.
[1] U.S. Food and Drug Administration. FDA approves new treatment for certain digestive tract cancers (Lutathera). January 26, 2018.
View source ↗[2] European Medicines Agency. Lutathera (lutetium 177Lu oxodotreotide) Summary of Product Characteristics (EMA EPAR).
View source ↗[3] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of
177Lu-Dotatate for Midgut Neuroendocrine Tumors (NETTER-1).
N Engl J Med. 2017;376(2):125-135.
View source ↗[4] Singh S, Halperin D, Myrehaug S, et al. [
177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2).
Lancet. 2024;403(10446):2807-2817.
View source ↗[5] Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for PRRT.
Pharmaceuticals (Basel). 2019;12(3):114.
View source ↗[6] Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: PRRT.
Neuroendocrinology. 2017;105(3):295-309.
View source ↗[7] Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2020;31(7):844-860.
View source ↗[8] Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with
68Ga-DOTA-conjugated somatostatin receptor targeting peptides.
Eur J Nucl Med Mol Imaging. 2017;44(9):1588-1601.
View source ↗[9] Strosberg JR, Caplin ME, Kunz PL, et al.
177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut NETs (NETTER-1): final overall survival.
Lancet Oncol. 2021;22(12):1752-1763.
View source ↗[10] U.S. Food and Drug Administration. FDA expands indication for Lutathera (lutetium Lu 177 dotatate) for gastroenteropancreatic neuroendocrine tumors (April 2024).
View source ↗[11] Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2013;40(5):800-816.
View source ↗[12] Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with NETs: the value and limitations of clinical factors.
Eur J Nucl Med Mol Imaging. 2015;42(1):5-19.
View source ↗[13] Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [
177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.
Clin Cancer Res. 2017;23(16):4617-4624.
View source ↗[14] NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. National Comprehensive Cancer Network.
View source ↗[15] Yadav MP, Ballal S, Bal C, et al. Efficacy and Safety of
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Advanced Metastatic Neuroendocrine Tumors.
Indian J Nucl Med. 2019;34(4):265-272.
View source ↗[16] Parghane RV, Talole S, Prabhash K, Basu S. Clinical Response Profile of
177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumors: An Indian Institutional Experience.
Clin Nucl Med. 2017;42(6):428-435.
View source ↗[17] Atomic Energy Regulatory Board (Government of India). Safety Code for Nuclear Medicine Facilities. AERB/RF-MED/SC-2 (Rev. 2).
View source ↗[18] Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [
111In-DTPA-D-Phe1]-octreotide.
Ann N Y Acad Sci. 1994;733:496-506.
View source ↗[19] Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [
177Lu-DOTA0,Tyr3]octreotate (Erasmus cohort).
Eur J Nucl Med Mol Imaging. 2003;30(3):417-422.
View source ↗[20] Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID).
J Clin Oncol. 2009;27(28):4656-4663.
View source ↗[21] Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors (CLARINET).
N Engl J Med. 2014;371(3):224-233.
View source ↗[22] Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors (RADIANT-3).
N Engl J Med. 2011;364(6):514-523.
View source ↗[23] Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
N Engl J Med. 2011;364(6):501-513.
View source ↗[24] Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in NETs: Radiological, Nuclear Medicine and Hybrid Imaging.
Neuroendocrinology. 2017;105(3):212-244.
View source ↗[25] Strosberg JR, Wolin E, Chasen B, et al. Health-Related Quality of Life in Patients With Progressive Midgut NETs Treated With
177Lu-Dotatate in the Phase III NETTER-1 Trial.
J Clin Oncol. 2018;36(25):2578-2584.
View source ↗[26] Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges.
Nat Rev Drug Discov. 2020;19(9):589-608.
View source ↗[27] van Vliet EI, Hermans JJ, de Ridder MA, et al. Tumor response assessment to treatment with [
177Lu-DOTA0,Tyr3]octreotate in patients with GEP-NETs.
J Nucl Med. 2013;54(10):1689-1696.
View source ↗[28] Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic NETs treated with
177Lu-D OTATATE.
Eur J Nucl Med Mol Imaging. 2017;44(3):490-499.
View source ↗[29] Garske-Román U, Sandström M, Fröss Baron K, et al. Prospective observational study of
177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasised NETs.
Eur J Nucl Med Mol Imaging. 2018;45(6):970-988.
View source ↗[30] Society of Nuclear Medicine and Molecular Imaging (SNMMI). Practice guideline for somatostatin receptor PET/CT and PRRT.
View source ↗
About the Author
Dr. Ishita B. Sen
MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York
Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA imaging and PSMA-directed radioligand therapy, with one of the largest Indian institutional experiences in Lu-PSMA.